Loading stock data…
RGEN
$125.61+7.40 (+6.26%)
Pre-Market$126.05+0.44 (+0.35%)· Last close May 5
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Repligen Corporation in the Healthcare sector is trading at $125.61. The stock is currently 29% below its 52-week high of $175.77, remaining 9.0% below its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why RGEN maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$125.61
Potential Downside
86.5%
Whystock Fair Value$16.93
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus18 analysts
Buy
Mean target$178.94+42.5%
Range$142.00 – $220.00
Fundamentals
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatogr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.43B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
132.58
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-0.66%
Volume
Today's trading volume
2.01M
Recent News
Repligen Reshapes Operations And China Reach As Valuation Signals Upside
Repligen (NasdaqGS:RGEN) has launched a Transformation Office focused on manufacturing optimization, IT modernization and broader operational changes. The company completed the divestiture of its non core Polymem business, simplifying its portfolio. Repligen entered an OEM partnership in China, targeting expanded reach in the Asia Pacific bioprocessing market. Repligen is a bioprocessing company that supplies tools and technologies used in biologic drug production, an area that remains...
Repligen Q1 Earnings Call Highlights
Repligen (NASDAQ:RGEN) reported first-quarter 2026 results that management said reflected broad-based demand across end markets and geographies, alongside margin expansion driven by mix, pricing, and volume leverage. The company also updated full-year guidance to reflect the divestiture of its Polym
Repligen Corporation Q1 2026 Earnings Call Summary
Moby summary of Repligen Corporation's Q1 2026 earnings call
Repligen (RGEN) Q1 2026 Earnings Call Transcript
Olivier Loeillot: Thank you, Jacob. Great execution once again by our team enabled us to deliver 15% reported revenue growth or 11% organic and 160 basis points of adjusted operating margin expansion. This includes the launch of our transformation office, the associated sale of the polymer business and a new partnership in China.
Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates
Repligen (RGEN) delivered earnings and revenue surprises of +24.97% and +1.53%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?